Trials / Completed
CompletedNCT00723957
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Patients With Advanced Non-small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 260 (actual)
- Sponsor
- R-Pharm · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixabepilone, 32 mg/m^2 | Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2 |
| DRUG | Paclitaxel, 200 mg/m^2 | IV solutions, paclitaxel, 200 mg/m\^2 |
| DRUG | Carboplatin (area under the concentration curve [AUC] 6) | Carboplatin (AUC 6) day 1, every 21 days, 6 cycles |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2010-05-01
- Completion
- 2011-08-01
- First posted
- 2008-07-29
- Last updated
- 2020-10-28
- Results posted
- 2011-10-17
Locations
33 sites across 10 countries: United States, Argentina, Australia, France, Germany, Italy, Russia, South Korea, Spain, Taiwan
Source: ClinicalTrials.gov record NCT00723957. Inclusion in this directory is not an endorsement.